Non-hodgkin Lymphoma Developing After Discontinuation of Direct-acting Antiviral Treatment for Hepatitis C: A Case Report
Journal Title: Viral Hepatitis Journal - Year 2019, Vol 25, Issue 1
Abstract
Today, direct-acting antivirals (DAA) are the main treatment options for hepatitis C infection. However, whether malignancy risk is increased after DAA treatment is a matter of debate. Conflicting results have been reported in the relevant studies. In this paper, we present the case of B-cell non-Hodgkin lymphoma developing after DAA treatment in a patient with complete response to hepatitis C treatment.
Authors and Affiliations
Oğuz Karabay, Ertuğrul Güçlü, Tuba Hacıbekiroğlu, Mustafa Kösem
Keywords
Related Articles
- EP ID EP551635
- DOI 10.4274/vhd.galenos.2018.0029
- Views 35
- Downloads 0
Failure of Direct-Acting Antiviral Agents Due to Incomplete Hepatitis C Virus Genotyping
Current direct-acting antivirals (DAAs) have high success rates in the treatment of chronic hepatitis C virus (HCV) infection. However, 1-15% of patients fail to achieve viral eradication. Some factors may play a role in...
Human Pegivirus (GB Virus Type C) and Its Relationship with HIV
Editorial
Distribution of Hepatitis C Virus Genotypes in Aydın Province
Objectives: In this study, we evaulated the distribution and alteration of hepatitis C virus (HCV) genotypes throughout years which has a clinical importance in the treatment and follow-up. Materials and Methods: Test re...
How to Diagnosis the Occult Hepatitis C Virus?
Editorial
Assessment of Quality of Life of Patients with Chronic Hepatitis B and C Treated with Pegylated Interferon-alpha
Objectives: It was aimed to evaluate health-related quality of life of patients with non-cirrhotic chronic hepatitis B (CHB) and chronic hepatitis C (CHC) during interferon therapy with the standard short form-36 (SF-36)...